Results 211 to 220 of about 371,575 (291)

Glofitamab in combination with immunochemotherapy in patients with relapsed/refractory B‐cell non‐Hodgkin lymphoma: Phase 1b dose‐escalation study

British Journal of Haematology, EarlyView.
Summary Glofitamab was investigated with obinutuzumab/rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (G/R‐CHOP) in patients with relapsed/refractory B‐cell non‐Hodgkin lymphoma (B‐NHL) who had ≥1 prior obinutuzumab/rituximab‐containing therapy (NCT03467373). The primary end‐point was to determine the optimal biological dose of
William Townsend, Nilanjan Ghosh, Martin Hutchings, Michael Dickinson, Monica Tani, Armando Santoro, Michael Crump, Amitkumar Mehta, Reinhard Marks, Martin Weisser, Martin Barrett, Chun Wu, Derrick Kaufman, Katharina Lechner, Pauline Baumlin, Pontus Lundberg, Max S. Topp   +16 more
wiley   +1 more source

Design and implementation of a hybrid machine learning framework for predicting heart rate status. [PDF]

Sci Rep
Emami M, Salehbagheri N, Rajebi S, Pedrammehr S, Shirini K.   +4 more
europepmc   +1 more source

SAKK 35/14 randomized trial of rituximab with or without ibrutinib for patients with untreated follicular lymphoma

British Journal of Haematology, EarlyView.
Summary The randomized phase II SAKK 35/14 trial, conducted by the Swiss Group for Clinical Cancer Research (SAKK) and the Nordic Lymphoma Group (NLG), compared efficacy and safety of rituximab (375 mg/m2 intravenously for 4 weeks followed by maintenance every 2 months for 24 months) plus placebo (arm A) versus the same schedule of rituximab plus ...
Maria Cristina Pirosa, Marianne Brodtkorb, Sämi Schär, Björn E. Wahlin, Micaela Hernberg, Michael Pedersen, Anastasios Stathis, Thilo Zander, Urban Novak, Thorsten Zenz, Natalie Fischer, Fatime Krasniqi, Felicitas Hitz, Ann‐Sofie Johansson, David Löfgren, Peter Albert Meyer, Anne Turid Bjørnevik, Giulio Sartori, Stefanie Hayoz, Andrea Fuhrer, Luzia Steiner, Francesco Bertoni, Luca Ceriani, Stefan Dirnhofer, Emanuele Zucca, Bjørn Østenstad   +25 more
wiley   +1 more source

To vary or not to vary: A flexible empirical Bayes factor for testing variance components

British Journal of Mathematical and Statistical Psychology, EarlyView.
Abstract Random effects are the gold standard for capturing structural heterogeneity, such as individual differences or temporal dependence. Yet testing their presence is difficult because variance components are constrained to be non‐negative, creating a boundary problem. This paper introduces a flexible empirical Bayes factor (EBF) for testing random
Fabio Vieira, Hongwei Zhao, Joris Mulder
wiley   +1 more source

Machine Learning and Metabolomics to Characterize Warburg-Like Metabolic Subtypes in Human Retinal Endothelial Cells Exposed to Risk Factors Associated With Proliferative Diabetic Retinopathy. [PDF]

Transl Vis Sci Technol
Sbei O, Eltanani S, Ibrahim S, Yumnamcha T, Srinivas SP, Ibrahim AS.   +5 more
europepmc   +1 more source

Novel approaches for drug development against chronic primary pain: A systematic review

British Journal of Pharmacology, EarlyView.
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus, Éva Borbély, Andreas Goebel, Ralf Baron, Zsófia Hajna, Zsuzsanna Helyes   +5 more
wiley   +1 more source

Design and Evaluation of an Edge AI-Enabled Low-Power Magnetic Sensor for Real-Time Road Traffic Monitoring. [PDF]

Sensors (Basel)
Hodoň M, Šarafín P, Formanek L, Kociánová A.   +3 more
europepmc   +1 more source

Association of altered body composition with cardiac wasting in cancer with and without cardiotoxic therapy

British Journal of Pharmacology, EarlyView.
Created in BioRender: Scientific Figure and Illustration Software. Background and Purpose In advanced cancer, associations among changes in body composition, cardiac wasting and prior cardiotoxic anticancer therapy have not been investigated. Experimental Approach Using bioelectrical impedance analysis (BIA), body composition was measured in 206 ...
Sara Hadzibegovic, Jonathan L. Hella, Jan Porthun, Alessia Lena, Danara Krug, Iulia Baluta, Ursula Wilkenshoff, Amir A. Mahabadi, Matthias Totzeck, Tienush Rassaf, Stefan D. Anker, Wolfram Doehner, Ulrich Keller, Lars Bullinger, Dominik P. Modest, Barry J. A. Laird, Richard J. E. Skipworth, John G. F. Cleland, Christian Oeing, Stephan von Haehling, Ulf Landmesser, Markus S. Anker   +21 more
wiley   +1 more source

Comprehensive Genomic Profiling Beyond Driver Testing in Non‐Squamous Non‐Small Cell Lung Cancer With Known Drivers

Cancer Science, EarlyView.
Figure 6 Comprehensive genomic profiling identified additional actionable alterations in a substantial proportion of patients with non‐squamous NSCLC despite previously identified driver alterations, with some findings leading to subsequent matched targeted therapies.
Yoshihiro Masui, Tatsuya Yoshida, Yoh Yamaguchi, Jun Miyakoshi, Ryoko Inaba Higashiyama, Akiko Tateishi, Yuki Shinno, Yuji Matsumoto, Yusuke Okuma, Tomonori Mizutani, Hidehito Horinouchi, Kouya Shiraishi, Takashi Kohno, Takafumi Koyama, Noboru Yamamoto, Yasushi Goto   +15 more
wiley   +1 more source

Artificial Intelligence in Predicting Postoperative Nausea and Vomiting Among Surgical Patients Following General Anesthesia: A Systematic Review. [PDF]

Cureus
Ramanujam V, Carneiro S, Ramanujam K, Arthur A, Addisu E, Chouhan SN.   +5 more
europepmc   +1 more source